Cencora, Inc. (NYSE:COR) Shares Bought by Trust Co. of Toledo NA OH

Trust Co. of Toledo NA OH lifted its holdings in Cencora, Inc. (NYSE:COR) by 32.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,358 shares of the company’s stock after acquiring an additional 334 shares during the period. Trust Co. of Toledo NA OH’s holdings in Cencora were worth $305,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in COR. Czech National Bank grew its holdings in Cencora by 7.0% during the 4th quarter. Czech National Bank now owns 38,025 shares of the company’s stock valued at $8,543,000 after purchasing an additional 2,489 shares in the last quarter. Graypoint LLC grew its holdings in Cencora by 8.2% during the 4th quarter. Graypoint LLC now owns 1,267 shares of the company’s stock valued at $285,000 after purchasing an additional 96 shares in the last quarter. ORG Partners LLC grew its holdings in Cencora by 17.4% during the 4th quarter. ORG Partners LLC now owns 426 shares of the company’s stock valued at $96,000 after purchasing an additional 63 shares in the last quarter. First Hawaiian Bank grew its holdings in Cencora by 7.0% during the 4th quarter. First Hawaiian Bank now owns 10,654 shares of the company’s stock valued at $2,394,000 after purchasing an additional 701 shares in the last quarter. Finally, Range Financial Group LLC grew its holdings in Cencora by 272.8% during the 4th quarter. Range Financial Group LLC now owns 9,114 shares of the company’s stock valued at $2,048,000 after purchasing an additional 6,669 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on COR shares. Evercore ISI raised their price target on shares of Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Wells Fargo & Company lowered their price target on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a report on Friday, December 13th. UBS Group increased their price objective on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Bank of America reiterated a “neutral” rating and set a $245.00 price objective (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Finally, Barclays increased their price objective on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $275.60.

Insider Transactions at Cencora

In related news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the completion of the sale, the chairman now owns 306,752 shares in the company, valued at approximately $74,283,064.32. This represents a 6.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 94,696 shares of company stock worth $22,862,734. 15.80% of the stock is currently owned by insiders.

Cencora Trading Down 0.0 %

Cencora stock opened at $236.10 on Tuesday. The firm’s 50-day moving average is $237.82 and its 200-day moving average is $233.54. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $253.27. The company has a market cap of $45.63 billion, a P/E ratio of 31.44, a PEG ratio of 1.54 and a beta of 0.49.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were given a $0.55 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.93%. The ex-dividend date of this dividend was Friday, November 15th. Cencora’s dividend payout ratio (DPR) is presently 29.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.